Consensus eFFECTOR Therapeutics, Inc.

Equities

EFTR

US28202V2079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1.81 ^USD	-2.16%		+1.69%	-84.51%

Apr. 04	Health Care Down on Retreat From Risk -- Health Care Roundup	DJ
Apr. 04	Top Midday Decliners	MT

Evolution of the average Target Price on eFFECTOR Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0300d4b.Ji-KYY9AnFfbSwjD4Rw-P9L_Ur8_mHupB8yDOlO3u4s.YxnAD8cz6CSNDUe7lXp0eKapBOVr7jebXqGxeD7469lDWu4zxwTvOZkzUQ~5e7bc0cfd6bfc3307c19a29af61311f8

Analyst Recommendations on eFFECTOR Therapeutics, Inc.

HC Wainwright Starts eFFECTOR Therapeutics With Buy Rating, $5 Price Target	23-08-24	MT
Stifel Upgrades eFFECTOR Therapeutics to Buy From Hold, Adjusts Price Target to $7 From $1.30	23-05-26	MT
Credit Suisse Trims eFFECTOR Therapeutics' Price Target to $5.50 From $7, Keeps Outperform Rating	23-05-10	MT
Credit Suisse Adjusts eFFECTOR Therapeutics' Price Target to $7 From $8, Keeps Outperform Rating	23-03-09	MT
JMP Securities Trims Price Target on eFFECTOR Therapeutics to $1 From $2, Maintains Market Outperform Rating	23-01-09	MT
Credit Suisse Lowers eFFECTOR Therapeutics' Price Target to $8 From $10, Keeps Outperform Rating	23-01-06	MT
JMP Securities Trims Price Target on eFFECTOR Therapeutics to $2 From $5, Maintains Market Outperform Rating	22-11-17	MT
JMP Securities Lowers eFFECTOR Therapeutics' Price Target to $5 From $8, Market Outperform Rating Kept	22-08-11	MT
Credit Suisse Lowers eFFECTOR Therapeutics' PT to $10 from $12, Says Funding for Key Readouts In Place; Maintains Outperform Rating	22-08-10	MT
Credit Suisse Lowers eFFECTOR Therapeutics' Price Target to $12 from $14, Keeps Outperform Rating	22-05-11	MT
Credit Suisse Lowers eFFECTOR Therapeutics' Price Target to $14 from $16, Keeps Outperform Rating	22-03-17	MT
Stifel Reinstates Coverage of eFFECTOR Therapeutics With Hold Rating, $4 Price Target	22-03-17	MT
Credit Suisse Lowers eFFECTOR Therapeutics' Price Target to $16 from $20 to Reflect Changes in Tomivosertib Program, Keeps Outperform Rating	22-01-25	MT
Stifel Downgrades EFFECTOR Therapeutics to Hold From Buy, Adjusts Price Target to $6.20 From $20	22-01-25	MT
JMP Securities Adjusts eFFECTOR Therapeutics' Price Target to $8 from $33, Keeps Market Outperform Rating	22-01-25	MT
Stifel Upgrades EFFECTOR Therapeutics to Buy From Hold; Price Target is $20	21-11-09	MT
EFFECTOR THERAPEUTICS : Credit Suisse Starts eFFECTOR Therapeutics at Outperform with $20 PT, Says Current Share Price Offers Attractive Entry Point Ahead of Meaningful Catalysts	21-10-12	MT
EFFECTOR THERAPEUTICS : Credit Suisse Starts eFFECTOR Therapeutics at Outperform With $20 Price Target	21-10-12	MT
EFFECTOR THERAPEUTICS : Mizuho Securities Starts eFFECTOR Therapeutics at Buy With $20 Price Target	21-10-04	MT
EFFECTOR THERAPEUTICS : JMP Securities Starts eFFECTOR Therapeutics at Market Outperform with $33 Price Target	21-09-21	MT
EFFECTOR THERAPEUTICS : Stifel Starts eFFECTOR Therapeutics at Hold with $20 Price Target	21-09-20	MT
EFFECTOR THERAPEUTICS : Cantor Fitzgerald Starts eFFECTOR Therapeutics at Overweight With $50 Price Target	21-09-13	MT